p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry
Language English Country Slovakia Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
10732868
Knihovny.cz E-resources
- MeSH
- Transcriptional Activation MeSH
- Adult MeSH
- Immunohistochemistry methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- Tumor Cells, Cultured MeSH
- Tumor Suppressor Protein p53 analysis genetics MeSH
- Breast Neoplasms chemistry MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Tumor Suppressor Protein p53 MeSH
The prognostic and predictive value of p53 mutation in breast cancer is still conflicting. The choice of the p53 status detection method may account for some discrepancies. In this pilot study we compared two differently-based methods for detection of p53 alteration in 32 breast carcinoma samples: the immunohistochemical method using Bp53, DO1 and DO11 monoclonal antibodies for analysis of the p53 protein accumulation in cell nuclei and the functional method FASAY. FASAY - functional analysis of the separated alleles in yeast - tests the capability of the human p53 to transactivate a reporter with a p53 binding site RGC driving the ADE2 gene in yeast. In our group the percentage of breast cancers with accumulated p53 protein was 50%, as well as percentage of mutant p53 scored by FASAY was 50%. Although the agreement of both methods, when comparing the results of individual patients was high (94%), our results show that immunohistochemistry does not reflect the p53 status quite exactly.
High frequency of temperature-sensitive mutants of p53 in glioblastoma
